Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)

Abstract Objective To examine the effect of the COVID‐19 pandemic on gonadorelin analogue prescription for community patients in England. Materials and methods We included data from all primary‐care patients who had relevant prescriptions dispensed in the community in England. Descriptive statistics...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ravina Barrett, Robert Barrett, Kalyan Dhar, Brian Birch
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	COVID‐19 follow‐up gonadotropin‐releasing hormone hormonal therapy male prostate cancer Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/e95d206610af445d9381e8d08adb7b54
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e95d206610af445d9381e8d08adb7b54
record_format	dspace
spelling	oai:doaj.org-article:e95d206610af445d9381e8d08adb7b542021-11-17T16:19:36ZGonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)2688-452610.1002/bco2.101https://doaj.org/article/e95d206610af445d9381e8d08adb7b542021-11-01T00:00:00Zhttps://doi.org/10.1002/bco2.101https://doaj.org/toc/2688-4526Abstract Objective To examine the effect of the COVID‐19 pandemic on gonadorelin analogue prescription for community patients in England. Materials and methods We included data from all primary‐care patients who had relevant prescriptions dispensed in the community in England. Descriptive statistics and interrupted time series analysis over 22 months (15 months before and 7 months after lockdown) was evaluated. Results A total of 22 months’ worth of data were analyzed (or 1 041 638 total items, monthly average 47 347 items). Goserelin; leuprorelin, and triptorelin are the medicines most used by total quantity in the study period. Simple descriptive statistics show that mean values have declined during the pandemic. The Interrupted Time Series (ARIMA Modeling) shows declining trends. After the pandemic's onset, we observe a statistically significant downward trend for goserelin (P = .017) and leuprorelin (P = .014). As these are the major constituents of the model, we interpret this overall data as showing a significant downward category trend. Aside from linearity, a significant step change was noted for leuprorelin (P = .029) showing an increase in prescription items with a similar effect that is close to being statistically significant for goserelin (P = .051). The actual cost of medicines shows minimal variation suggesting that prices of individual medicines have remained stable. The regional data showed variation but this was not statistically significant. In all cases, the Oct‐20 figures are lower “year on year.” This novel work reports the impact of a global pandemic on prescription volumes of prostate cancer (PCa) medicines. Conclusions A worrying decrease in prescription medicines raises concerns for the care of PCa patients. We encourage diagnosed patients to discuss their planned care with their doctor.Ravina BarrettRobert BarrettKalyan DharBrian BirchWileyarticleCOVID‐19follow‐upgonadotropin‐releasing hormonehormonal therapymaleprostate cancerDiseases of the genitourinary system. UrologyRC870-923ENBJUI Compass, Vol 2, Iss 6, Pp 419-427 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID‐19 follow‐up gonadotropin‐releasing hormone hormonal therapy male prostate cancer Diseases of the genitourinary system. Urology RC870-923
spellingShingle	COVID‐19 follow‐up gonadotropin‐releasing hormone hormonal therapy male prostate cancer Diseases of the genitourinary system. Urology RC870-923 Ravina Barrett Robert Barrett Kalyan Dhar Brian Birch Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)
description	Abstract Objective To examine the effect of the COVID‐19 pandemic on gonadorelin analogue prescription for community patients in England. Materials and methods We included data from all primary‐care patients who had relevant prescriptions dispensed in the community in England. Descriptive statistics and interrupted time series analysis over 22 months (15 months before and 7 months after lockdown) was evaluated. Results A total of 22 months’ worth of data were analyzed (or 1 041 638 total items, monthly average 47 347 items). Goserelin; leuprorelin, and triptorelin are the medicines most used by total quantity in the study period. Simple descriptive statistics show that mean values have declined during the pandemic. The Interrupted Time Series (ARIMA Modeling) shows declining trends. After the pandemic's onset, we observe a statistically significant downward trend for goserelin (P = .017) and leuprorelin (P = .014). As these are the major constituents of the model, we interpret this overall data as showing a significant downward category trend. Aside from linearity, a significant step change was noted for leuprorelin (P = .029) showing an increase in prescription items with a similar effect that is close to being statistically significant for goserelin (P = .051). The actual cost of medicines shows minimal variation suggesting that prices of individual medicines have remained stable. The regional data showed variation but this was not statistically significant. In all cases, the Oct‐20 figures are lower “year on year.” This novel work reports the impact of a global pandemic on prescription volumes of prostate cancer (PCa) medicines. Conclusions A worrying decrease in prescription medicines raises concerns for the care of PCa patients. We encourage diagnosed patients to discuss their planned care with their doctor.
format	article
author	Ravina Barrett Robert Barrett Kalyan Dhar Brian Birch
author_facet	Ravina Barrett Robert Barrett Kalyan Dhar Brian Birch
author_sort	Ravina Barrett
title	Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)
title_short	Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)
title_full	Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)
title_fullStr	Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)
title_full_unstemmed	Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)
title_sort	gonadorelins adherence in prostate cancer: a time‐series analysis of england’s national prescriptions during the covid‐19 pandemic (from jan 2019 to oct 2020)
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/e95d206610af445d9381e8d08adb7b54
work_keys_str_mv	AT ravinabarrett gonadorelinsadherenceinprostatecanceratimeseriesanalysisofenglandsnationalprescriptionsduringthecovid19pandemicfromjan2019tooct2020 AT robertbarrett gonadorelinsadherenceinprostatecanceratimeseriesanalysisofenglandsnationalprescriptionsduringthecovid19pandemicfromjan2019tooct2020 AT kalyandhar gonadorelinsadherenceinprostatecanceratimeseriesanalysisofenglandsnationalprescriptionsduringthecovid19pandemicfromjan2019tooct2020 AT brianbirch gonadorelinsadherenceinprostatecanceratimeseriesanalysisofenglandsnationalprescriptionsduringthecovid19pandemicfromjan2019tooct2020
_version_	1718425451236425728

Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)

Ejemplares similares